Академический Документы
Профессиональный Документы
Культура Документы
S. No.
1.
Content
INTRODUCTON
-Medicinal
&
Aromatic
2.
3.
PRODUCT
3.1
PROFILE
3.2
CHARACTERISTICS
3.3
4.
4.1
4.2
5.
EUROPEAN TRADE
5.1
EU TRADE VOLUME
5.2
6.
GERMANY
6.1
MARKET POTENTIAL
6.2
FEATURES OF TRADING
6.3
TRADE STRUCTURE
7.
INDIA
7.1
STRENGTHS/MARKET SHARE
7.2
8.
8.1
8.2
CURRENT CHALLENGE
8.3
9.
BARRIERS TO TRADE
10.
11.
Plants
APPENDICES
Appendix No.
APPENDIX
1.
2.
STANDARD ORGANISATIONS
3.
4.
TRADE ASSOCIATIONS
5.
6.
TRADE PRESS
7.
[MAPs]
8.
9.
10.
1. INTRODUCTION
Medicinal plants, since times immemorial, have been used in virtually all cultures as a
source of medicine. The widespread use of herbal remedies and healthcare preparations, as
those described in ancient texts such as the Vedas and the Bible, and obtained from
commonly used traditional herbs and medicinal plants, has been traced to the occurrence of
natural products with medicinal properties.
The demand for plants and plant-based drugs of proven therapeutic value within traditional
medical systems such as Ayurveda, Unani Tibb, and Chinese medicine has never been
higher. In many countries, including India, traditional medicine is becoming more widely
appreciated within all segments of society. Due to population growth and increasing
urbanization, the demand for plant-based drugs is rising very rapidly in cities and towns.
Worldwide, the increased popularity of non-Western treatments ("alternative" or
complementary medicine) is creating a rapidly expanding market for both crude drugs and
sophisticated compound preparations. The global annual trade in herbal drugs has recently
been estimated at US$14 billion to over US$20 billion with the largest markets found in
Europe (-50% of global trade), Asia, and North America.
While we may welcome the growth of Ayurveda and other traditional medical systems, we
should be very seriously concerned about other trends that jeopardize the future availability
of Ayurveda's plant drug sources. Healthy, diverse forests and other natural ecosystems that
are the source of the overwhelming bulk of medicinal plants are being degraded,
fragmented and disappearing altogether at alarming rates in many parts of the world. At the
same time, the cultural diversity and traditional ecological knowledge of the uses and
medicinal value of biodiversity that have been developed through millennia by countless
indigenous or tribal societies throughout the world is also on a downward spiral.
medicinally because trade statistics do not identify all the plants individually and of those
listed, the statistics do not identify medicinal and other uses separately. Products reported
as medicinal plants often include gums, spices and plants used in the food industry; certain
plant products include those used for teas and infusions; large volumes of plants such as
pyrethrum are used in manufacture of insecticides; plants used by the cosmetic industry are
also included'.
3.3 CUSTOMS/STATISTICAL PRODUCT CLASSIFICATION
On January 1, 1988, a unified coding system was introduced to harmonise the trading
classificationsystems used world-wide. This system is called the Harmonised Commodity
Description System (HS) and was developed by the World Customs Organisation(WCO). The
system comprises about 5,000 commodity groups, each identified by a six digit code,
arranged in alegal and logical structure and is supported by well defined rules to achieve
uniform classification.
Most of the natural ingredients used in the pharmaceutical industry do not have an exclusive
HS Code and are incorporated in a broader product code. As per the information available, a
four to six-digit list of the main product groups is mentioned below. These product groups
can be further divided into sub-groups to the extent of ten digits.
SITC &
HS
Codes Description
Code
SITC
292.4
Corresponding
HS or CCCN
code
1211
1211.10
1211.20
292.49 Other
1211.90
Other
-Mint leaves:
1211.90.20
Crude or not manufactured
00
1211.90.40 Other
20 - Herbal teas and herbal infusions (single species, unmixed)
40 Other
declined. There is some cultivation in Germany, where leading producers of herbal medicines
have their own plantations for popular products. Finzelberg, for example, cultivates St.
John's wort and echinacea in Germany. The area under cultivation, however, is small as
cultivation in Eastern European countries is much cheaper.
Eastern European countries such as Bulgaria, Hungary and Albania are major EU suppliers
of material from medicinal and aromatic plants.
5. EUROPEAN UNION
5.1 EU TRADE VOLUME
Table 1: List of importers for the selected product in 2001 Product: 121190 Plants
& pts of plants(incl. Seed & fruit) used in pharm, perf, insect etc
Value
Quantity
imported in
Quantity Unit value
Importers
imported
2001, in US$
unit
(US$/unit
in 2001
thousand
Annual
growth in
value
between
1997-2001,
%
Annual
growth in
value
between
2000-2001,
%
Annual
growth in
Quantity
between
1997-2001
Share in
world
imports,
%
World
estimation
850,662
432,129
Tons
1,969
-6
-2
-4
100
United State
of America
132,129
43,966
Tons
3,005
-4
-4
16
Japan
89,975
27,031
Tons
3,329
-3
-21
10
11
Germany
71,953
38,585
Tons
1,891
-15
-6
-15
France
56,353
18,585
Tons
3,032
-1
16
Hong
Kong(SARC)
43,139
27,613
Tons
1,562
-20
-14
-26
Korea, Rep.
of Korea
39,122
33,689
Tons
1,161
-6
-3
-24
Italy
36,048
12,039
Tons
2,994
-6
-3
-4
United
Kingdom
33,418
6,915
Tons
4,833
-5
-4
Canada
29,418
No
quantity
Malaysia
26,705
14,595
Tons
1,830
-5
-9
Singapore
22,021
4,493
Tons
4,901
-8
-2
Spain
21,784
11,461
Tons
1,901
-10
-2
-10
The above table indicates that among top 12 importing countries having 69% of total import
shares for medicinal and aromatic plants in the year 2001, the share of EU countries was
26%.
In 2000, Germany was, by far, the leading EU importer of medicinal & aromatic plants.
Between 1998 and 2000, however, Germany saw its share in EU imports decrease from 38
percent to 29 percent, while the United Kingdom experienced an increase from 7 to 12
percent. The Netherlands was small importer of medicinal & aromatic plants, being only the
12th leading EU importer.
The major importing markets are the EU and USA. In these countries, increased
demand for medicinal plants is being fuelled primarily by consumer interest in natural
products and remedies, as well as by increasing concerns about the possible side effects of
allopathic medicines. Major developing countries such as China and India are exporting
medicinal plants, herbal tonics, cosmetics, perfumes etc. There are therefore good prospects
for export growth from LDCs in this market. However, markets in developed countries for
herbal medicine -especially in Europe and the USA - are highly regulated and are
very difficult to penetrate, particularly for developing countries and LDCs whose
products have not undergone the stringent tests applied by developed country
pharmaceutical manufacturers before mass production.
Sales of herbal medicine alone were estimated to have exceeded US$ 12.5 billion in 1994
and US$ 30 billion in 2000, with annual growth rates averaging between 5% to 15%,
depending on the region. Meanwhile, the herbal supplements market has had a higher
annual average growth rate between 1990-1997 of 25%. Rising global interest in medicinal
plants has also created a sustained and largely 'underground' trade in plant materials, many
of which are being collected in LDCs in an unregulated manner, resulting in indiscriminate
harvest of wild varieties and serious damage to bio-diversity.
However, there is still a general lack of knowledge within the world market
about the whole range of traditional remedies available, and demand will grow as
knowledge increases. The issue of consumer safety is increasingly important with the
USA recently prohibiting the sale of some Chinese products. The developing countries
will need to pay increasing attention to this issue.
The entry of large pharmaceutical and Over-The- Counter (OTC) companies has
placed botanical medicines more strongly on the mass market.
Increased advertising budgets and media attention for botanical medicines have
Increased emphasis on safety, efficacy and quality has resulted in more research and
development, a shift towards standardized products, and requirements for highquality raw materials. This expanded research and development has improved the
legitimacy of botanical medicines.
Some claim that the innovation and expansion of the pharmaceutical biotechnology
sector, which is based on natural materials, has produced a scientific and financial
environment open to the potential medical benefits of other natural products,
including botanicals.
Moreover, more and more innovative companies are requesting organically certified raw
material or value added products, especially for the development of new products. There is
increasing demand for certified raw material and value added products.
6. GERMANY
6.1 MARKET POTENTIAL
European-based companies and German companies in particular, dominate the global herbal
supply industry. The biggest herbal raw materials group is Martin Bauer Group, a Germanbased corporation with annual sales of over US$ 250 million. About 4,000 to 6,000
botanicals are of commercial importance. It has been reported that between 500 and 600
medicinal plants are traded via Hamburg, which made it the world's leading trading centre in
plants. However, the position of Hamburg has decreased in recent years. Manufacturers of
herbal medicines used to acquire their raw materials from traders, but now some have their
own plantations or have direct contacts with producers. Manufacturers of herbal products
are increasingly interested in having direct relationships with producers of the required
materials, in order to ensure a sustained source and/or to save costs. Exporters should
realize that the Internet is an important medium in the sourcing of raw materials for herbal
products. A number of users/traders of natural ingredients mentioned that they use the
Internet in order to find new suppliers.
Indicati
ve
potenti
Germany's imports from
al trade
world
in US$
thousan
d
Value Annual Share in Value Annual Quanti Quanti Value Annual Quantity
2001 in growt German 2001 in growt
ty
ty unit 2001 in growt 2001(ton
US$
h in
y's
US$
h in 2001
US$
h in
ns)
thousa value imports, thousa value
thousa value
nd
betwe
%
nd
betwe
nd
betwe
en
19972001,
%
en
19972001,
%
40
2,594
-13
en
19972001,
%
9
Tons
1,234
-4
695
40
19
Tons
1,809
139
19
4 72,199
-2 39,082
Tons 71,953
-15
38,045
69,35
9
-50
The above table indicates that in respect of three major product groups of MAPs being
imported by Germany, only one product group is being exported by India to Germany.
Therefore, there is a good scope for exporting the other two product groups, which are any
how being exported by India to some other countries in the world.
Europe is a major world trader in MAPs. At least 2,000 MAP species are traded, of which two
thirds (1,200-1,300 species) are native to the continent. The most popular botanical
medicines sold in Europe in 1996 were formulated from gingko, ginseng, garlic, echinacea
and evening primrose.
About a quarter of global imports of MAPs each year are into Europe. In 1992-90, imports to
Europe came from more than 120 countries, with 60 per cent of material coming from
outside Europe, mainly from Africa and Asia. Between 1985 and 1995, the average annual
growth rate in the European market was 10 per cent, with 440,000 tonnes imported in 1996
valued at US$1.3 billion. This is now likely to have risen to well above 500,000 tonnes.
Germany is the leading European importer, accounting for a third of both the total volume
and the total value of European imports, with France, Italy, Spain and the UK among the
other
12
leading
importing
countries.
The 12 leading exporting countries in Europe are led by Germany, Bulgaria and
Poland, with Germany accounting for a fifth of the volume and a third of the value.
Germany has a large re-export trade. Between 1992 and 1996, Europe exported an average
of 70,000 tonnes of MAPs annually, 20 per cent to non-European destinations, mainly North
America. Sixty per cent of exports were from just five European countries -Germany,
France, Italy, Spain and the UK.
Germany is the major European trader in MAPs, being the pivotal country in intraEuropean trade and acting as a link between markets in eastern and south-eastern Europe
and those in the north and west. The German phytomedical market grew at 30 per cent
between 1993 and 1995, from a value of US$2.5 billion to US$3.26 billion. The estimated
growth rate in 1998-99 was 5- 10 per cent.
The UK is the fourth largest market in Europe. Britain lost direct access to suppliers in
eastern Europe after the fall of communism, the trade becoming directed to an even greater
extent than previously through Germany. Activities are currently under way to re-establish
and strengthen former trade links between the UK and eastern Europe.
UK trade restrictions differ from those of the rest of Europe. For example, bloodroot,
Sanguinaria canadensis, is restricted in the UK and much of the small trade in this product is
re-exported to Europe. There is very little overlap in the UK between trading systems for
traditional European herbal medicines, TCMs(Traditional Chinese Medicines), Ayurvedic and
Unani medicines. Of the 704 medicinal plant species which have been identified as being
traded in the UK, 290 species are used exclusively in TCM with only 33 "cross-over" species
used both in TCM and western herbal medicine. Imports of TCM materials were reported to
be worth about 3 million per annum, which is far smaller than the western herbal trade.
Raw materials for Ayurvedic and Unani medicines tend to be imported directly by individual
practitioners on an informal basis.
Bulgaria is the most important source country for European MAPs, with average net exports
of 7,000 tonnes per annum. Sixty to seventy per cent of MAPs produced or harvested in
Bulgaria are exported, mainly to wholesalers in Germany. Bulgarcoop, a cooperative
enterprise instituted under the communist regime, is still the main national dealer in MAPs,
even in this post-communist era. This cooperative helps growers with cultivation and
guarantees to buy an agreed harvest. Since the fall of communism, 50-60 private and small
companies, often family-owned, have joined the MAP trade and founded the Private Herb
Exchange, which provides similar help to growers to Bulgarcoop and also organises courses
for collectors. Turkey exports approximately 28,000 tonnes of MAPs annually, generating
nearly US$50 million.
In producer countries generally, the plant material is bought from collectors and
cultivators by various types of traders, including local dealers, village cooperatives
The number of outlets for MAPs reflects their diversity of uses. Material of a species
which has entered the wholesale or manufacturing sectors may have originated from
various harvesting areas within countries, or it could even have been imported. This
makes it very difficult to identify sources of materials and to impose quality controls.
The lengths of trade chains and the perceived need to protect information lead to a
lack of transparency. A direct consequence is that those at the start of the chains
(producer and collectors) have little idea of the market value of the MAPs which they
are supplying , nor the means opt discover the value added from source to end-use.
In India and Nepal, some NGOs are working to make market information available to
collectors in order to give them bargaining power. The lack of transparency means
that it is difficult to influence the trade easily in order to improve the sustainability of
the source of MAPs.
In former Eastern Bloc countries, the trade has changed in recent years from strictly
organised , state-controlled systems based mostly on cuntry-wide networks, to free
and diversified markets with the increasing number of competing private companies.
This has had significant negative effects on the sustainability and conservation of
MAPs because previous quotas and controls are nw largely ignored. Only Bulgaria still
has a relatively well controlled MAP trade.
7. INDIA
7.1 INDIA'S STRENGTHS / MARKET SHARE: [Relation vis A vis Rivals]
Table: List of exporters for the selected product in 2001
Product:121190 Plants &pts of plants(incl sed &fruit)usd in pharm,perf,insect etc.
Annual
Annual
Annual
Value
growth in growth in growth in Share in
exported in Quantity
Report in
Quantity unit value
value
quantity
value
world
Exporters 2001, in exported
Comtrade
unit
(US$/unit) between
between
between exports,
US$
in 2001
in 2001
19971997-2001, 2000-2001,
%
thousand
2001,%
%
%
World
estimation
760,178
563,407
Tons
1,349
-6
100
China
144,109
160,687
Tons
897
-12
-7
19
India
72,199
39,082
Tons
1,847
-2
17
France
51,946
8,002
Tons
6,492
10
-3
-2
United
States of
America
50,707
14,986
Tons
3,384
-3
-20
Germany
50,374
13,139
Tons
3,834
-10
-5
-6
India enjoys being the second largest exporter of medicinal and aromatic plants in the world
sharing the 9% of the total world export as per the table above. It is also indicates that
India leads Germany in export of above MAP product group by 2% share because Germany
exports only 7% of total market share on exports.
7.2 INDIA IS A MAJOR EXPORTER OF RAW MAPS
India is a major exporter of raw MAPs and processed plant-based drugs. Exports of crude
drugs from India in 1994-95 were valued at US$53,219 million and of essential oils
US$13,250 million. Important crude drugs included Plantago ovata (psyllium), Panax spp.
(ginseng), Cassia spp. (senna) and Catharanthus roseus (rosy periwinkle). Essential oils
included Santalum album (sandalwood), Mentha arvensis (peppermint) and Cymbopogon
flexuosus (lemongrass). Seventy-five per cent of total exports from India are sent to six
countries -France, Germany, Japan, Switzerland, the UK and the US. Other major importers
are Bangladesh, Pakistan and Spain.
The leading developing country suppliers of medicinal & aromatic plants to the EU were
China, India, Egypt, Morocco, Chile, Turkey, and Albania. The imports of medicinal plants
considerably.
100
39,082
Tons
1,847
-2
17
United
States of 40,947
America
72,199
-6
57
18,601
Tons
2,201
-5
-3
29
16
-4
Japan
5,029
4,711
Tons
1,068
11
11
32
11
-3
France
4,620
1,796
Tons
2,572
15
10
62
Italy
3,371
429
Tons
7,858
-35
-6
Germany 2,594
1,825
Tons
1,421
-13
-17
-15
United
2,355
Kingdom
1,010
Tons
2,332
-12
Germany is the fifth largest importer of MAPs, wherein the leaders are USA, Japan, France
and Italy.
8. ROLE OF DEVELOPING COUNTRIES
8.1 As suppliers for Medicinal & Aromatic Plants
In 2000, developing countries were particularly strong in the supply of medicinal & aromatic
plants, accounting for 40 percent of imports by EU member countries in terms of value and
54 percent of imports by EU member countries in terms of volume. Since 1998, the share of
developing countries in EU imports has fluctuated closely around these levels. China and
India, as a result of their long tradition in the field of natural medicine and their vast land
area, comprising all climatic zones, were leading producers of natural ingredients for
pharmaceuticals. demand for kava kava which is endemic to the South Pacific. Vanuatu is
another Pacific island which profited from the increased demand. After 1998, EU imports
8.2 Conservation and sustainable use of medicinal plant resources: the current
challenge
In spite of their significant contributions to public health and local or national economies,
sound data regarding either the number or volume of medicinal plant species harvested
from wild sources for local or commercial use are generally lacking, or at best very
incomplete, in most countries. However, the few studies that have examined this topic
strongly suggest that with relatively few exceptions, the overwhelming majority of plant
drugs used in Ayurveda and other traditional systems of medicine are derived from plants
collected from the wild, and mainly from forests.
In China, for example, an estimated 5,000 species are used in traditional medicine. The
annual demand for these plant drugs exceeds 700,000 tons, 80% of which are from wild
sources, with an in-country market value of US$1.4 billion. In Indonesia, a total of 1260
species of medicinal plants are reportedly sold in markets, most of which are collected from
forests. In South Africa, between 400 and 500 species are commonly sold for traditional
medicinal use, of which 99% are harvested from wild sources. In Germany, 1543 medicinal
plant species are in import and export trade, 70-90% of which are harvested primarily from
the wild. In exports of medicinal raw materials, India ranks second next to China, which
exports an estimated 32,600 tons per year valued at US$46 million.
As noted earlier, rising commercial demand for wild-source plant drugs in some countries
(including India) is occurring against a backdrop of rapid deforestation and/or degradation
of species-rich forest ecosystems. The direct and underlying causes of deforestation in most
countries currently facing this challenge are numerous, often complex, and related to
variety of social, economic and political issues, including the failure to assess and
avoid/mitigate the negative impacts of non-forest sector (i.e., agriculture, transportation,
energy, trade, etc...) policies and developments on forests and biodiversity more generally.
Over-exploitation of medicinal plants from wild sources is only one of many cumulative,
unsustainable uses of forests leading to their degradation and devaluation, although its
impact can be locally severe.
With reference to the exploitation of medicinal plants, a number of inter-related factors in
addition to those responsible for forest loss have contributed to the over-harvesting and
depletion of key plant species, consequent degradation of forest resources, and the erosion
A shift from subsistence (local) use to commercial sale has in many locales
resulted in larger volumes of certain species being harvested beyond sustainable
levels. Increased commercialization of medicinal plants (and other forest products)
often has significant effects on traditional resource tenure and user-right
arrangements, particularly in relation to tribal communities. This process is often
linked to more general shifts from subsistence to cash economies and to the erosion
of traditional cultural and religious values within forest-dependent communities.
The process of urbanization has increased urban market demand for plant drugs the
influence of these markets on rural resource exploitation.
Expanding international trade often increases the demand and market prices for
particular species, resulting in rapid resource depletion, as has been historically the
case for a variety of timber and non-wood forest products from tropical forests since
the 19th century.
There are an increasing number of plant species of known medicinal value that are
threatened with extinction in the wild in the short- or medium-term. For example, the
IUCN1 Red List of Threatened Species includes, for India, a total of 319 terrestrial plant
species, of which a significant proportion are used in traditional systems of medicine,
including Ayurveda. Threatened and endangered higher plants in South India include 36
medicinally important species, including such well-known species as Saraca asoca (Asoka),
Pterocarpus santalinus (Raktacandana) and Rauvolfia serpentina (Sarpagandha).
Considering that the conservation status of only a very small percentage of plant species
has been assessed, the total number of threatened medicinal plant species in India can be
projected to be in the hundreds.
Current rates of forest loss, forest degradation and depletion (or loss) of wild populations of
medicinal plants represent a serious threat to the future of traditional medicine, to the wellbeing of the majority of the world's population who depend directly on plant drugs for their
health care needs, and to the capacity of forests to provide a broad spectrum of essential
environmental goods and services. Reversing these trends, and thereby ensuring the future
supply of high-quality plant drugs, is a monumental task, but one that is compatible with
the large number of local, national and international efforts aimed at fulfilling the noble
objectives of the Convention on Biological Diversity, i.e., conservation of biological diversity,
sustainable use of components of biological diversity, and fair and equitable sharing of the
benefits arising out of the use of genetic resources. The resolution of challenges related to
the conservation and sustainable use of medicinal plant resources is a major test for the
CBD, its Global Strategy for Plant Conservation, and the network of local-to-global
organizations and initiatives that will determine the success of the CBD.
BOTTLENECKS/CONSTRAINTS
Medicinal plants have received low priority in national investment, research and export
development; as they tend to be considered minor crops. Most LDCs concentrate their
research and development on staple crops such as rice and wheat.
Threats to the future development of medicinal plant exports from LDCs depend on the
structure of the major importing markets. Despite large import potential for medicinal plants
in developed countries, market development is constrained by several factors:
Capital and R&D:- The capital requirements and R&D facilities needed for entering
into major markets such as Germany and France are too costly for small LDC
exporters. Their entry into the countries where herbal medicines are not sold as
over-the-counter products is also made difficult, as distribution outside food outlets
is hard to access and risks are incurred by selling in unlicensed markets without
being able to make claims of benefits.
MSTQ:- LDC exporters lack systems of measurement, standards, testing and quality
(MSTQ) required by exporters to ensure their products meet international standards
Lack of knowledge of supply:- Few, if any, LDCs have carried out an inventory of
species and sustainable off-take on the basis of gathering or limited husbandry.
Prospects for cultivation are yet to be studied. The supply potential is thus virtually
unknown. At present, few LDCs have the resources and the institutional capability to
advise on policy and regulatory mechanisms to provide consistently high-quality
products. Know-how in processing technologies is also deficient, as is the availability
of sustainable production processes.
Market access:- Market access issues have also constrained LDC export
development. Generally, most medicinal plants and crude drugs are allowed without
any tariff restrictions in several countries. They are exempt from import duty in
Canada, Japan, the European Union and the USA. However, tariff charges in China
and South Africa vary between 10% and 20% of the value of goods, depending on
product and origin, while Japan levies a 5% tax on imports of ginseng roots, peppy
straw, sandalwood and some others.
9. BARRIERS TO TRADE
European Union has a number of regulations to regulate the trade in pharmaceutical sector.
The export market in EU is quite large as indicated by import of Indian medicines as Food
supplements but the import is impeded by EU regulations. The tariff rates on products
related to Medicinal & Aromatic Plants can be referred from the websites mentioned below:-
http://www.wto.org/English/tratog_e/schedules_e/goods_schedules_e.htm
We may need the relevant HS codes for these products, which can be obtained from
the World Customs Organization httg://www.wcoomd.org/ie/index.html
also
be
consulted
for
more
information
Association
of
European
Self-medication
http://www.aesgg.be /links2.html = Herbal medicinal products.
http://pharmacos.eudra.org then
go
to
http:// europa.eu.int/comm/research/headlines/12-2001.html
regarding
Industry:
Pharmaceuticals.
An example can be given of a product code 1211903000 Tonquin beans, wherein the TB and
NTB are given in the following table:for product: 1211903000 Tonquin beans
Tariffs and non-tariff
measures
Tariff
advalorem
MFN duties
3%
GSP rate
0%
0%
Tariff
specific
Non-tariff measures or
product description
0%
0%
0.6%
Opportunities for Exporters It is not easy to present an overview of promising products for
exporters from developing countries. However, some important points that emerge are
mentioned below. There is a big transfer of natural ingredients from developing countries to
the pharmaceutical industry for research purposes. Large pharmaceutical companies are
engaged in bio-prospecting, which refers to the exploration of biodiversity for commercially
valuable genetic and biochemical resources. This type of trade in natural ingredients is
research-driven. Pharmaceutical companies study the properties and effects of specific
medicinal plants and the knowledge is used with the aim to develop new medicines, which
can be patented.
This so-called bio-prospecting is strongly dominated and controlled by large pharmaceutical
companies. Exporters from developing countries will find more opportunities in the trade of
ingredients with known properties and effects, which are not patented and which can be
traded freely.
In Europe, some 2,000 medicinal and aromatic plants are used on a commercial basis. A
number of botanical species are consistently cited by industry representatives in the USA
and Europe as the most important today, and likely in the next five years. Echinacea was
cited as the top product now and in the years to come, in both the USA and Europe.
European companies continue to consider St Johns wort and Kava kava extremely
important, while USA industry representatives tended to think both might be in decline due
to controversial recent studies and bad press. Other important botanicals cited include:
Gingko, Ginseng, Valerian, Goldenseal, and Garlic. USA companies also cited Black cohosh
and Astragalus as good performers, while European, companies have had continued success
with Hawthorn and Chamomile. Most buyers in The Netherlands are not interested in plant
material, but in plant extracts. There are only a few developing countries which are able to
supply extracts conforming to the requirements of western industry.
having gained market knowledge must be to map the areas in which they occur naturally
and attempt to estimate sustainable off-take. The available species should then be market
tested by laboratories and end-users in Europe and the USA to determine which of the
available species have the highest market potential. Having identified the scale of the
opportunity, the next step would be to examine husbandry and/or cultivation methods, at
which point firmer estimates could be made of supply potential. An active programme of
marketing herbs and plants to end-users should follow this.
Explore Alternative sales techniques
Alternative sales techniques are also available to the LDCs by taking advantage of the
Internet. Dietary supplement sales on the Internet reached US$ 40 million in 1998, an
increase of $12 million over 1997 figures. This accounts for only 0.3% of the total 1998 US
supplement market of $13.6 billion. However, the rate of sales growth for supplements on
the Internet far exceeds that of natural foods stores, mass-market stores, and multilevel
marketing.
Improved information and awareness-raising
At present there are significant gaps in the knowledge of the present consumption and
projected future demands, as well as trade statistics, for the vast number of plant drugs
that are locally used and that enter into local, national and international. In the absence of
such information, informed decision-making and planning by industry, policy-makers,
medicinal plant producers (or forest managers for wild-source plant drugs), and research
and development organizations is severely impaired. There is a critical need to compile,
synthesize, and make widely available such information. Major marketing organizations,
industrial phytomedicine producers, government agencies, and research institutions all have
important roles to play in this regard. At the international level, several organizations have
been active in promoting and coordinating such activities, notably the TRAFFIC wildlife trade
monitoring program.
There is a similar, perhaps more severe, dearth of reliable information on the present and
projected future supplies of medicinal plants from wild sources. While there are significant
efforts by a variety of organizations at local, regional, national and international levels to
monitor and evaluate the changing conditions and conservation status of forest ecosystems
and their constituent species, greater public support for such efforts is needed.
In recent years there has been a dramatic increase in the numbers of useful databases,
publications synthesizing and popularizing medicinal plant information, as well as growing
public debate and media coverage of traditional medicine and its links to biodiversity
conservation and other issues such as intellectual property rights and cultural preservation2.
Additional efforts are needed, however, to increase public awareness of the value of
medicinal plant resources and their role in public health, and of the importance of
conservation and sustainable management of natural forests and other biodiversity-rich
habitats for the continued survival and production of valued plant drug sources. Broadened
public awareness of the ecological, social and economic importance of healthy natural
ecosystems needs to be translated into more active public involvement and political support
for conservation and sustainable forest management. Closely linked to this is the need for
increased consumer and producer awareness and support willingness to pay for plant drugs
derived from sustainable forest management systems. Unless there are sufficient financial
incentives to market medicinal plants (or plant parts) collected non-destructively and at
sustainable levels, markets (in most countries) will continue to be dominated by plant drugs
from "mined", rather than from sustainably managed, wild sources. In some national and
Agencies and programs of the United Nations, as well as international treaties, conventions
and forums operating under their auspices, are also extremely important elements of the
broad array of organizations and activities undertaken at the international level that
contribute to the resolution of issues related to medicinal plant conservation, management,
development and trade. Several UN agencies serve critical roles in highlighting relevant
issues, facilitating international policy and scientific dialogue, and provide mechanisms and
coordinate support for effective international collaboration. These include: UNESCO (which
administers the Man and the Biosphere program - http://www.unesco.org/mab/), FAO
(specifically FAOs Forestry Department -http://www.fao.ora/forestry/ - which coordinates
the ongoing UN Forum on Forests), UNEP (http://www.unep.orgl - which administers the
Convention
on
Biological
Diversity),
the
World
Health
Organization
(http://www.who.int/en/),
and
the
World
Intellectual
Property
Organization
(http://www.wipo.int/ - which seeks to address issues related to intellectual property rights
at the heart of many international disputes over access and benefit-sharing vis--vis
medicinal plants and their derivatives)
APPENDIX I
TRADE FAIR ORGANISERS
AUSTRIA
IGM
International Horticultural Exhibition, cut flowers and plants
Frequency: annual (28 August-1 September 2003)
Address:
Email:
messe@tulln.at
Internet:
www.tulln.at/messe
DEENMARK
DAN-GAR- TEK/DAN-PLANT
technology, cut flowers, pot plants
Frequency: biennial (August 2003)
Address:
Email:
adm@occ.dk
Internet:
www.occ.dk
FRANCE
Florissimo
International exhibition fair for exotic flowers and foliage
Frequency: every 4 years (March 2004)
Address:
Cedex, France
Telephone: +33 (0)3 80773900
Fax:
Email:
congrexpodijon@exnet.fa
Hortiflor
Florist's trade fair, cut flowers and pot plants
Frequency: annual (8-10 March 2003)
Address:
GERMANY
IPM
International trade fair for cut flowers and plants, equipment and florists' requisites
Frequency: annual (30 January- 2 February 2003)
Address:
E-mail:
zoppa@essen-tradeshows.com
Internet:
www.ipm-messe.de
Internet:
www.messe-essen.de
E-mail:
info@koelnmesse.de
Internet:
www.koelnmesse.de
ITALY
Miflor
Email:
info@padovafiere.it
Internet:
www.padovafiere.it
THE NETHERLANDS
International Hortifair
Equipment, flowers and plants
Frequency: annual (5-8 November 2003)
Address:
+31 (0)205491894
Email:
waal@rai.nl
Internet:
www.flowertradeshow.nl or www.hortifair.nl
SPAIN
Iberflora
garden and horticultural technology show
Frequency: annual, (17-19 October 2003)
Address:
FMIV, Avenida de las Ferias s/n, P.O. Box 476,46080 Valencia, Spain
Email:
feriavalencia@feriavalencia.com
Internet:
www.feriavalencia.com
UNITED KINGDOM
Horticulture
International Flower & Plant Trade Exhibition
Frequency: biennial (February 2003)
Address:
Nexus Media Ltd, Nexus House, Swanley, Kent BR8 8HU, United Kingdom
Email:
nxhort@nexusmedia.com
IFTEX
International Flower & Plant Trade Exhibition
Frequency: biennial (September 2003)
Address:
Nexus Media Ltd, Nexus House, Swanley, Kent BR8 8HU, United Kingdom
Email:
nxhort@nexusmedia.com
Telephone:
+41 (0)227912111
Fax:
+41 (0)227913111
E-mail:
info@who.int
Internet:
www.who.org
EUROPEAN UNION
European Agency for the Evaluation of Medicinal Products (EMEA)
Address:
Telephone:
Fax:
Internet:
www.eudra.org
Telephone:
+ 32 (0)2 5500811
Fax:
+ 32 (0)25500819
E-mail:
infodesk@cenclcbel.be
internet:
www.cenorm.be
AUSTRIA
sterreichisches Normungsinstitut (ON)
Address:
Telephone:
+ 43 (0)1 21300
Fax:
E-mail:
infostelle@on-norm.at
Internet:
www.on-norm.at
BELGIUM
Institute Beige de Normalisation (IBN)
Address:
Telephone:
+ 32 (0)273801 11
Fax:
+ 32 (0)2 733 42 64
E-mail:
info@ibn.be
Internet:
www.ibn.be
DENMARK
Dansk Standard (DS)
Address:
Telephone:
+ 45 (0)39 9661 01
Fax:
+ 45 (0)399661 02
E-mail:
dansk.standard@ds.dk
Internet:
www.ds.dk
FINLAND
Suomen standardisoimisllito r.y. (SFS)
Address:
Telephone:
Fax:
E-mail:
info@sfs.fi
Internet:
http://www.sfs.fi
FRANCE
Association Francaise de Normalisation
Address:
Telephone:
+ 33 (0)1 42915555
Fax:
+ 33 (0)1 42915656
Internet:
www.afnor.fr
GERMANY
Deutsches Institut fr Normung eV (DIN)
Address:
Telephone:
+ 49 (0)302601 0
Fax:
+ 49 (0)302601 1231
E-mail:
postmaster@din.de
Internet:
www.din.de
GREECE
Hellenic Organisation for Standardisation
Address:
Telephone:
+ 30 (0)1 2120100
Fax:
+ 30 (0)1 2286219
E-mail:
info@elot.gr
Internet:
www.elot.gr
ITALY
Ente Nazionale Italiano di Unificazione (UNI)
Address:
Telephone:
+ 39 02 700241
Fax:
+ 39 02 70106106
E-mail:
uni@uni.unicei.it
Internet:
www.unicei.it
IRELAND
National standards Authority of Ireland (NSAI)
Address:
Telephone:
Fax:
E-mail:
nsai@nsai.ie
Internet:
www.nsai.ie
LUXEMBOURG
Service de l'Energie de l'Etat (SEE)
Address:
Telephone:
Fax:
+ 352 (0)46 97 46 39
E-mail:
see.norrnalisation@eg.etat.lu
Internet:
www.etat.lu/see
THE NETHERLANDS
Nederlands Normalisatie Instituut (NNI)
Netherlands Standardisation Institute
Address:
Telephone:
+ 31 (0)152690390
Fax:
+ 31 (0)152690190
E-mail:
info@nni.nl
Internet:
www.nni.nl
PORTUGAL
Instituto portugus Da Qualidade (Ipq)
Address:
Telephone:
Fax:
E-mail:
ipq@mail.ipq.pt
Internet:
www.ipq.pt
SPAIN
Asociacin Espaola de Normalizacin y Certificacin
(AENOR)
Address:
Telephone:
+ 34 (0)91 4326000
Fax:
+ 34 (0)913104032
E-mail:
info@aenor.es
Internet:
www.aenor.es
SWEDEN
Standardiseringen i Sverige (SIS)
Address:
Telephone:
+ 46 (0)8-6103000
Fax:
+ 46 (0)8-307757
E-mail:
info@sis.se
Internet:
www.sis.se
UNITED KINGDOM
British Standards Institution (BSI)
Address:
Telephone:
+ 44 (0)208 996 90 00
Fax:
+ 44 (0)208 996 74 00
E-mail:
info@bsi.org.uk
Internet:
www.bsi.org.uk
Telephone:
+ 41 (0)227300111
Fax:
+ 41 (0)227334439
E-mail:
itcreg@intracen.org
Internet:
www.intracen.org
+ 44 (0)1892533813
Fax:
+ 44 (0)1892 544895
E-mail:
marketing@public-Iedger.com
Internet:
www.public-ledger.com
INTERNET
Herb crop shop
(at Herb Growing and Marketing Network)
www.herbworld.com/cropshop
Sites for retail prices for herbal materials include:
www.herbmarket.com/
http://libertynatural.com
Telephone:
+ 32 (0)2 735 51 30
Fax:
+ 32 (0)2 735 52 22
E-mail:
info@aesgp.be
Internet:
www.aesgp.be
Telephone:
+ 32 (0)26262555
Fax:
+ 32 (0)26262566
E-mail:
info@efpia.org
Internet:
www.efpia.org
Telephone:
+ 32 (0)2777 9977
Fax:
E-mail:
euro.keys@euro-keys.com
Internet:
www.girp.org or www.euro-keys.com
Argyle House, Gandy Street, Exeter, Devon, EX4 3LS, United Kingdom
Telephone:
+ 44 (0)1392424626
Fax:
+ 44 (0)1392424864
Internet:
www.exeter.ac.uk/phytonet/escop.html
Naredi
Federation
Address:
Telephone:
+ 32 (0)2 2186679
Fax:
+ 32 (0)2 2177900
Email:
info@naredi.be
Internet:
www.naredi.be
Nehoma
Association of Netherlands producers and importers of phytomedicines
Address:
Telephone:
+ 31 (0)525686001
Fax:
+ 31 (0)525685905
Email:
info@nehoma.nl
Internet:
www.nehoma.nl
Neprofarm
Association of the Netherlands Self-Medication Industry
Address:
Telephone:
+ 31 (0)35 6970821
Fax:
+ 31 (0)35 6970822
E-mail:
info@neprofann.nl
Internet:
www.neprofann.nl
Telephone:
+ 31 (0)341 554023
Fax:
+ 31 (0)341561772
E-mail:
secretariaat@natuur-gezondheidsproducten.nl
Internet:
www.natuur-gezondheidsproducten.nl/
ipecac, emetic and dysentery cure from Central American Cephaelis spp.
Alepidea amatymbica
Skin infections
Dicoma anomala
Wounds and sores
FLUIDS
4. General body aches and pains; arthritis and rheumatism
Malva parviflora
5. Hypertension/diabetes
Sutherlandia frutescens
Trifolium burchelianum
Melolobiun alpinium
Tephrosia semiglabra
Malawi
1. Malaria
Aristolochia petersiana
2. Anaemia
Acalypha sinensis
5. Childhood diseases, such as measles
Ceratotheca sesamoides
6. Sexually transmitted diseases (general)
Tamarindus indica
Syphilis
Cassia petersiana
Zambia
1. Malaria
Dialiopsis Africana
Pterocarpus angolensis
2. Upper respiratory tract infection(bronchitis)
Mangifera indica
3. Diarrhoea
Erythrina abyssinica
Cinchona succirubra
Cinchona ledgeriana
Cinchona hybrid
Artemisa afra
Azadirachta indica
2. Diabetes mellitus
Centella asiatica
Runex urambarensis
3. Epilepsy
Hyptis suaveolens
Vismianthus punctatus
Ficus bursei
4. Gonorrhoea
Ozoroa mucronata
Markhania obtusfolia
5. Asthma
Grewia sulcata
Telephone:
+ 49 (0)34663256-14
Fax:
+ 49 (0)3466 3256-20
Telephone:
+ 49 (0)58459881-0
Fax:
+ 49 (0)58459881-11
E-mail:
mail@agrimedia.com
Internet:
www.agrimedia.com
ITALY
AGRO food INDUSTRY
Addresss:
Telephone:
+ 39024818011
Fax:
+ 39024818070
E-mail:
mickycar@tin.it
Internet:
www.teknoscienze.com
Fitoterapia
Addresss:
Telephone:
+ 3902 574961
Fax:
+ 390257404620
E-mail:
indenami@tin.it
Internet:
www.indena.it/fitotrp.htm
UNITED KINGDOM
European Journal of Herbal Medicine
National Institute of Medical Herbalists
Addresss:
Telephone:
Fax:
+ 44 (0)1392498963
E-mail:
editor@ejhm.co.uk
Internet:
www.ejhm.co.uk
Nutraceuticals International
Addresss:
Telephone:
Fax:
+ 44 (0)2078280415
E-mail:
editorial@marketletter.com
Telephone:
Fax:
E-mail:
cabi@cabi.org
Internet:
http://hort.cabweb.org/Arornatic/ramphome.htm
INTERNATIONAL
Herbalgram American Botanical Council
Addresss: P.O. Box 144 345, Austin, TX 78714-4345,
USA
Telephone:
1-512-926-4900
Fax:
1-512-926-2345
Internet:
www.herbalgram.org
Address:
Telephone:
Fax:
+ 1 6077226362
E-mail:
getinfo@haworthpressinc.com
Internet:
www.haworthpressinc.com
Telephone:
+ 16192957685
Fax:
+ I 6192955743
E-mail:
info@nutritionbusiness.com
Internet:
www.nutritionbusiness.com
Telephone:
+31 (0)102013434
Fax:
+31 (0)104114081
Email:
cbi@accessguide.nl
Internet:
www.cbi.nl/accessguide
Telephone:
+ 31 (0)703587528
Fax:
+ 31 (0)703587528
Internet:
www.ctf.nl
Telephone:
+41 (0)229178139/40
Fax:
E-mail:
cites@unep.ch
Internet:
www.cites.org
Telephone:
+ 44 (0)1908365200
Fax:
+ 44 (0)1908265252
E-mail:
fids@btinternet.corn
Internet:
www.ingridnet.corn
Telephone:
Fax:
+ 44 (0)207278 1142
E-mail:
earthinfo@earthscan.co.uk
Internet:
www.earthscan.co.uk
Telephone:
Fax:
+ 32 (0)2219 7342
E-mail:
info@icmap.org
Internet:
www.eas.be
Telephone:
+ 33 (0)388412883
Fax:
+ 33 (0)38841 2771
E-mail:
info@pheur.org
Internet:
www.pheur.org
Telephone:
+ 52 (0)95146905
Fax:
+52(0)95162110
Email:
fscoax@fscoax.org
Internet:
www.fscoax.org
Dag-Hammarskjold-Weg 1-5,
65760 Echborn, Germany
Telephone:
+ 49 (0)619679-0
Fax:
+ 49 (0)619679-1115
E-mail:
postmaster@gtz.de
Internet:
www.gtz.de
Telephone:
Fax:
+ 33 (0)149532942
E-mail:
icc@iccwbo.org
Internet:
www.iccwbo.org
Telephone:
+ 31 (0)246844301
Fax:
+ 31 (0)246844301
Email:
nvf@fyto.nl
Internet:
www.fyto.nl
Telephone:
+ 31 (0)384268181
Fax:
+ 31 (0)384213063
E-mail:
info@skal.com
Internet:
www.skal.com
Traffic Europe (Joint wildlife trade monitoring programme of WWF and IUCN)
Address:
Telephone:
Fax:
E-mail:
traffic_europe@cornpuserve.com
Internet:
www.traffic.org
E-mail:
info@icmap.org
Internet:
www.icmap.org
Telephone:
+ 49 (0)5327 86810
Fax:
+ 49 (0)5327 5420
E-mail:
info@galke.com
Internet:
www.galke.com
Telephone:
+ 49 (0)9181 23190
Fax:
+ 49 (0)9181231265
E-mail:
info@bionorica.de
Internet:
www.bionorica.de
3. Buchler GmbH
Trading house for quinine
Address:
Harxbutteler StraBe 3,
0-38110 Braunschweig, Germany
Telephone:
+ 49 (0)5307 93121
Fax:
+ 49 (0)5307 93131
E-mail:
reineche@buchler-gmbh.com
Internet:
www.guinine-buchler.com
Telephone:
+ 49 (0)210349940
Fax:
+ 49 (0)228 4220593
E-mail:
info@cealo.des
5. DHU
Homeopathy
Address:
Telephone:
+ 49 (0)721409301
Fax:
+ 49 (0)7214093263
E-mail:
info@dhu.de
Internet:
www.dhu.de
6. Finzelberg
Bio-extracts for the pharmaceutical industry.
Address:
Telephone:
+ 49 (0)2632 9240
Fax:
+ 49 (0)2632 924040
E-mail:
welcome@finzelberg.de
Internet:
www.finzelberg.de
7. Gehrlicher
Produce all galeric forms of phyto-extracts from more than
400 medicinal and useful plants for the pharmaceutical
cosmetic and food industry.
Address:
Telephone:
+ 49 (0)81798015
Fax:
+ 49 (0)8179 778
E-mail:
gehrlicher .extracts@t-online.de
Internet:
www.gehrlicher.de
Telephone:
+ 49 (0)4614902076
Fax:
+ 49 (0)461 4902077
E-mail:
generalextractproducts@t-online.de
Internet:
www.generalextractQroducts.com
Telephone:
+ 49 (0)40 736045-0
Fax:
+ 49 (0)40 736045-45
E-mail:
kaden.bio@t-online.de
Internet:
www.kaden.de
Telephone:
+ 49 (0)4215239-0
Fax:
+ 49 (0)4215239-199
E-mail:
info@lamotte.de
Internet:
www.lamotte.de
Telephone:
+ 49 (0)3040370-0
Fax:
+ 49 (0)30 40370103
Internet:
www.lichtwer.de
12. Madaus AG
Development and manufacture of modern
phytopharmaceuticals.
Address:
Telephone:
+ 49 (0)2218998-0
Fax:
+ 49 (0)2218998- 701
E-mail:
info@madaus.de
Internet:
www.madaus.de
Dutendorfer Str. 5- 7,
D-91487 Vestenbergsgreuth, Germany
Telephone:
+ 49 (0) 9163-88-0
Fax:
+ 49 (0) 9163-88-312
E-mail:
welcome@martin-bauer.de
Internet:
www.martin-bauer.de
Telephone:
+ 49 (0)73140202
Fax:
+ 49 (0)731402532
E-mail:
info@ratiopharm.de
Internet:
www.ratiopharm.de
15. Salus-Haus
Address:
Telephone:
+ 49 (0)8062 9010
Fax:
+ 49 (0)8062 9147
E-mail:
info@salus.de
Internet:
www.salus.de
Telephone:
+ 49 (0)7614909161
Fax:
+ 49 (0)7614909125
E-mail:
info@spreewald-pharma.de
Internet:
www.spreewald-pharma.de
17. Weleda AG
Medicins and skincare products.
Address:
Telephone:
+ 49 (0)7171919-414
Fax:
+ 49 (0)7171919-424
E-mail:
dialog@Weleda.de
Internet:
www.weleda.de
20.
Finzelberg
Koblenzer
D-56603
Andernach
Germany
+49
(0
+49 (0 26 32) 92 40 40
GmbH
Stra8e
26
32)
&
Co.
24
KG
48-56
00
25.
Bosslerweg
D-73087
Bad
Germany
Wala-Heilmittel
GmbH
2
Boll
+49
+49 (0 7164) 9302 96
(07164)
9300
ITALY
Aboca di V. Mercati s.s. Az. Agraria
Address:
Telephone:
+ 3905757461
Fax:
+ 390575749130
E-mail:
info@aboca.it
Internet:
www.aboca.it
Bonomelli Srl
Address:
Telephone:
+ 390516170411
Fax:
+ 39051750571
E-Mail:
info@bonomelli.it
Internet:
www.bonomelli.it
Hammer Pharma
Herbal extracts.
Address:
Telephone:
+ 39029665121
Fax:
+ 390296651250
E-mail:
hammer@hammerpharma.it
Internet:
www.hammerpharma.it
Indena
Address:
Telephone:
+ 3902574961
Fax:
+ 3902 57496290
Internet:
www.indena.it
SPAIN
Extractos Natra
Producer of plant extracts, imports raw material
mainly from West Africa.
Address:
Telephone:
+ 34 (0)961920851152
Fax:
+ 34 (0)96 1920445
Internet:
www.natra-group.com
Telephone:
+ 34 (0)93 682 06 68
Fax:
+ 34 (0)936821647
E-mail:
lab@vinyals.com
Internet:
www.vinyals.com
UNITED KINGDOM
de Blac and Associates
Interest in trading with primary producers and
refiners of any natural products.
Address:
Telephone:
+ 44 (0)1788510058
Fax:
+ 44 (0)1788510057
E-mail:
sales@deblac.com
Internet:
www.deblac.com
48
Buckton Scott Group (B.S.G.)
Multi-national organisation active in manufacturing.
Address:
Telephone:
Fax:
E-mail:
info@buckton.co.uk
Internet:
www.buckton.com
StanChem International
Trading house for quinine.
Address:
Telephone:
+ 44 (0)1189580247
Fax:
+ 44 (0)1189589580
E-mail:
info@stanchem.co.uk
Internet:
www.stanchem.co.uk
Vitabiotics Ltd.
Interest in plant extracts.
Address:
Telephone:
Fax:
E-mail:
enquiries@vitabiotics.com
Internet:
www.vitabiotics.com
NETHERLANDS
American Sport
Manufacturer of food supplements, interest in plant
extracts.
Address:
Telephone:
+ 31 (0)204350010
Fax:
+ 31 (0)204350018
E-mail:
info@vitamins.nl
Internet:
www.vitamins.nl
Telephone:
+ 31 (0)302481010
Fax:
+ 31 (0)30 2414636
E-mail:
sales.dept.purchase@arnoldsuhr.nl
Internet:
www.arnoldsuhr.nl
Telephone:
+ 31 (0)134624100
Fax:
+ 31 (0)134624124
E-mail:
info@banpharm.com
internet:
www.banpharm.com
Biohorma
Raw plant material and plant extracts.
Address:
Telephone:
+ 31 (0)525 687200
Fax:
+ 31 (0)525 683932
E-mail:
info@biohorma.nl
Internet:
www.biohorma.nl
Telephone:
+ 31 (0)'94136420
Fax:
+ 31 (0)104047458
E-mail:
verkoop@caldic.nl
Internet:
www.caldic.nl
Telephone:
+ 31 (0)756479999
Fax:
+ 31 (0)75 6403830
E-mail:
jandekkernl@jandekker.com
Internet:
www.jandekker.com
BELGIUM
ORFFA Belgium Pharma B.V.
Provide a range of value-added specialist products to
the feed industry.
Address:
Industriepark, Ambachtsstraat 6,
B.1840 Londerzeel, Belgium
Telephone:
+ 32 (0)52319519
Fax:
+ 32 (0)52304275
Internet:
www.orffa.be
FRANCE
Arkopharma
Health care with plants.
Address:
+ 33 (0)49329 1128
E-mail:
info@arkopharma.corn
Internet:
www.arkopharma.corn
Barkem
Pure chemistry and vegetable extraction for pharmaceutical.
cosmetical and food industry.
Address:
Telephone:
+ 33 (0)553638106
Fax:
E-mail:
broken@berkern.corn
Internet:
www.berkern.corn
Guava tropical
Raw material importation, formulations in France,
worldwide trade and exclusive distributions.
Address:
Telephone:
+ 33 (0)143465243
Fax:
+ 33 (0)143461898
E-r nail:
info@guayapi.com
Internet:
www.guayapi.com
46
INDIA TRADE PROMOTION ORGANISATION
FRANKFURT
Services to Indian Trade & Industry
Dissemination of trade related information in specific products & services as per the
requirements of Indian manufacturers
Organizing Buyers Seller Meets with 4-5 month prior intimation from EPCs in India